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The review pinpoints operational concepts related to the redox biology network applied to the patho-
physiology and therapeutics of solid tumors. A sophisticated network of intrinsic and extrinsic cues,
integrated in the tumor niche, drives tumorigenesis and tumor progression. Critical mutations and
distorted redox signaling pathways orchestrate pathologic events inside cancer cells, resulting in re-
sistance to stress and death signals, aberrant proliferation and efﬁcient repair mechanisms. Additionally,
the complex inter-cellular crosstalk within the tumor niche, mediated by cytokines, redox-sensitive
danger signals (HMGB1) and exosomes, under the pressure of multiple stresses (oxidative, inﬂammatory,
metabolic), greatly contributes to the malignant phenotype. The tumor-associated inﬂammatory stress
and its suppressive action on the anti-tumor immune response are highlighted. We further emphasize
that ROS may act either as supporter or enemy of cancer cells, depending on the context. Oxidative
stress-based therapies, such as radiotherapy and photodynamic therapy, take advantage of the cytotoxic
face of ROS for killing tumor cells by a non-physiologically sudden, localized and intense oxidative burst.
The type of tumor cell death elicited by these therapies is discussed. Therapy outcome depends on the
differential sensitivity to oxidative stress of particular tumor cells, such as cancer stem cells, and
therefore co-therapies that transiently down-regulate their intrinsic antioxidant system hold great
promise. We draw attention on the consequences of the damage signals delivered by oxidative stress-
injured cells to neighboring and distant cells, and emphasize the beneﬁts of therapeutically triggered
immunologic cell death in metastatic cancer. An integrative approach should be applied when designing
therapeutic strategies in cancer, taking into consideration the mutational, metabolic, inﬂammatory and
oxidative status of tumor cells, cellular heterogeneity and the hypoxia map in the tumor niche, along
with the adjoining and systemic effects of oxidative stress-based therapies.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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Cancer is one of the main causes of death worldwide (see WHO
database at http://www-dep.iarc.fr/WHOdb/WHOdb.htm). It
brings a considerable economic and social burden despite in-
tensive research for deciphering its molecular mechanisms, and
for developing targeted therapeutic strategies using the persona-
lized medicine concept.
This review aims to summarize currently operational concepts
on the critical role of the intrinsic and microenvironmental oxi-
dative stress in sustaining cancer development and spreading. We
are particularly highlighting that reactive oxygen species (ROS)
may not only act as supporters of tumor cells, but can be turned
into their enemy that may be highly efﬁcacious in cancer
treatment.
It has been long proven that cancer cells display a pro-oxidative
shift [1] generated by: (1) chronic activation of various metabolic
sources of ROS, related to NADPH oxidases (NOXs 1–5 and dual
oxidases DUOX1/2) [2], alterations of mitochondrial DNA, oxida-
tive phosphorylation and energy metabolism, accompanied by
enhanced aerobic glycolysis [3]; (2) a dysfunctional antioxidant
response that is unable to counteract sustained production of ROS
during tumorigenesis [4]. This intracellular oxidative turmoil is
complemented by constant exposure of cancer cells to exogenous
ROS derived from anoxia-reoxygenation cycles [5], and from the
oxidative activity of tumor-inﬁltrating monocytes and neutrophils
[6].
Starting from the insidious oxidative stress in the tumor mi-
croenvironment, the review pinpoints without aiming to be ex-
haustive key genetic alterations and repair mechanisms, along
with critical turning points in redox signaling pathways, that
confer a survival advantage to cancer cells. Cancer is not a “all-or-
none” process, but integrates various cues into a pathologic net-
work of events and cellular responses in the tumor niche under
the pressure of multiple stresses (oxidative and inﬂammatory).
The therapeutic use of the cytotoxic face of ROS is exempliﬁed
by oxidative stress-based therapies, such as the radiotherapy and
photodynamic therapy. The mechanisms underlying the resistance
to an oxidative attack of particular cancer cells, such as cancer
steam cells, are highlighted. Finally, we show that the effects of
oxidative stress-based therapies go beyond local cytotoxicity,
being propagated in the close vicinity and having even a systemic
echo mediated by the immune response.2. Oxidative stress-induced genetic alterations and repair
mechanisms in cancer cells
Depending on its intensity and intracellular localization, oxi-
dative stress can alter mitochondrial and nuclear DNA. DNA da-
mage may include point mutations and single or double DNA
strand breaks. When the oxidative error is incorporated into cri-
tical genes, such as those involved in cell cycle control, important
cellular changes of metabolic rate and/or cellular response occur.Accordingly, point mutations that occur in cancer-associated genes
result in defective DNA repair, apoptosis and cell cycle deregula-
tion that sustain the malignant phenotype [7].
The most common forms of DNA alterations mediated by oxi-
dative stress are 8-oxoguanine and/or guanosine, induced by de-
regulated intracellular metabolism and uncontrolled oxidative
stress, as well as by injurious environmental factors, such as io-
nizing radiation.
mtDNA is more susceptible to oxidative damage than nuclear
DNA and basically contains a higher level of base damage, com-
monly 8-oxoguanine [8]. It has been shown that hydrogen per-
oxide or menadione-mediated 8-oxoguanine foci do not co-loca-
lize with y-H2AX(S139) foci that are a hallmark of DNA strand
breaks in the nuclear genome [9]. It is possible that these two
types of DNA damage are not inter-connected, or that exposure to
hydrogen peroxide or menadione may not always lead to single or
double strand breaks. This is consistent with previous studies
showing that 8-oxoguanine occurs more frequently in mitochon-
drial (mtDNA) than in nuclear DNA [7], but both genomes are
accumulating 8-oxoguanine with increasing age [10].
Oxidative phosphorylation in mitochondria is an important
source of ROS, with up to 4–5% of molecular oxygen picking up
electrons directly from the ﬂavin dehydrogenases and ubiquinol to
generate superoxide anion. Since mitochondrial DNA is not cov-
ered by histones, DNA-associated proteins are directly exposed to
ROS. Moreover, as mtDNA is intronless and has high transcription
rates, the probability of oxidative modiﬁcation of the coding re-
gion is increased [11–13]. Because mitochondrial respiration and
consequent production of ATP are key cellular events, oxidative
stress-induced damage of mitochondria and mtDNA may result in
reduced energy production, compromised cellular functions and
defective repair mechanisms. Therefore, oxidative damage of
mtDNA has been linked to the onset of various pathologic condi-
tions, such as neuronal degeneration, cardiovascular disorders,
reproductive malfunctioning, cancer and aging.
Divergences in cellular function can cause cycles of oxidative
damage that could contribute to cancer-related changes of phy-
siological functions. Genome variation can induce an important
shift of cellular responses towards oxidative damage. These pa-
thologic changes are induced by critical single-nucleotide poly-
morphisms (SNPs) that affect cell susceptibility to defective or
malfunctioning of encoded proteins. Most of the available data on
SNPs in cancer are provided by follow up studies focused on SNPs
that can predict the response or resistance of particular cancers to
chemotherapy. Some of these include ERCC polymorphisms in
non-small cell lung cancer, BRCA1 in mammary cancer, TMPRSS-
ERG in prostate cancer, certain phase II and III ABC transporters,
along with polymorphisms of oxidative damage response genes
(OGG1, GPX2/3 and SOD2/3) in renal cell carcinoma, lung, mam-
mary and prostate cancers [14,15].
The consequences of toxic and mutagenic stresses are mini-
mized in normal cells by speciﬁc repair mechanisms that con-
tinuously monitor DNA for maintaining genome integrity. Normal
cells respond to intracellular ROS generation by activating speciﬁc
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jured cells and to prevent further oxidative damage. Profound DNA
damage, such as DNA breaks, elicits base excision repair (BER), as
well as homologous recombination repair (HR). The removal of
ROS-induced base damage in mitochondrial and nuclear DNA is
mainly mediated by BER [16,17] through activation of damage-
speciﬁc DNA glycosylases [18]. A well-known example is the AP-
endonuclease OGG1 that is frequently mutated in renal cell car-
cinomas and is responsible for removal of ROS-mediated abasic
sites from DNA [19]. If 8-oxoguanine lesions are not removed be-
fore cells enter the S phase, they may be converted into lethal
single or double strand breaks during replication. Therefore, ubi-
quitous expression of AP-endonucleases is required for maintain-
ing genome integrity, and is regulated throughout the cell cycle in
most eukaryotic cells.3. Distorted redox signaling networks in cancer cells
ROS are key players in signal transduction, and redox reactions
are crucially involved in maintaining cellular homeostasis in
aerobic organisms [20]. From all metabolic ROS, hydrogen per-
oxide seems to have the attributes of a “second messenger” which
speciﬁcally interacts with effectors in signaling pathways [21]: it is
readily diffusible across membranes, and its chemistry, enzymatic
production and degradation provide adequate speciﬁcity for thiol
oxidation in thermodynamically favorable environments [22].
Being produced in discrete subcellular locations, ROS act as
local rheostats for intracellular signaling. Simple but highly tar-
geted changes induced in signaling molecules by oxidation–re-
duction reactions, in conjunction with the interplay of phosphor-
ylation–dephosphorylation, transduce messages from membrane
receptors to the nucleus. ROS-triggered formation of cysteine
sulfonic acid derivatives, disulﬁdes and glutathionylated proteins
results in conformational and functional changes of signaling
proteins [23]. Through a self-sustaining process (ROS-induced ROS
release) mediated by an inter-mitochondria signaling network
[24], the initial redox signal propagates within the cell and co-
ordinates the global signal transduction pattern. The location, in-
tensity and duration of the oxidative burst, along with inter-
connected redox-sensitive signaling pathways, decide whether
death or survival of normal and diseased cells occur in response to
physiologic stimuli and stressors. It is possible that cancer cells
derive from cells that adapted to a persistently smoldering intra-
and extracellular oxidative environment by developing potent
survival mechanisms [25]. Such death-resistant cells with accu-
mulating epi- or genetic abnormalities may lead to malignant
transformation.
Without aiming to be exhaustive, we present below some cri-
tical turning points in the signaling networks that sustain the
survival of tumor cells in an oxidative microenvironment by en-
hancing proliferation, resistance to death signals and ability to
repair damages.
3.1. Mitogen-activated protein kinases
The family of mitogen-activated protein kinases (MAPK),
comprising extracellular signal-regulated kinases ½ (ERK½), c-Jun
N-terminal kinases (JNK), and p38 MAPK [26], is a critical turning
point that drives cancer cells towards survival and proliferation,
instead of entering death pathways which are physiologically de-
signed to remove abnormal cells [27]. MAPKs are activated by
sequential phosphorylation mediated by upstream dual speciﬁcity
kinases MAPKKK, MAPKK and MAPK, and are inactivated by dual
speciﬁcity MAPK phosphatases [28]. MAPK pathway components
and upstream activators, such as the Ras oncogene, are sensitive toROS and are decisively involved in redox signaling [29,30].
MAPKs mediate opposing biological effects, depending on the
stimulus, type of activated MAPK, duration of kinase activation and
its subcellular localization [31]. Whilst uncontrolled activation of
ERK½ pathway sustains tumorigenesis, stress-induced activation
of JNK and p38 MAPK underlies the efﬁciency of cancer therapies
by controlling the balance of autophagy and apoptosis [32,33].
Activation of ERK½ is generally but not exclusively triggered by
receptor tyrosine kinases, resulting in cell proliferation and/or
resistance to cell death [32]. For example, the activation of ERK½
by the epithelial growth factor receptor (EGFR) induces ERK½
nuclear translocation and consequent cellular proliferation, while
direct activation of ERK½ by hydrogen peroxide leads to its re-
tention in the cytoplasm and mediates cytoprotective responses
[34].
The constitutive activation of ERK½ in cancer is partly derived
from gene mutations centered around the Ras–Raf axis, and is
associated to over-expression and/or mutation-driven activation of
receptor tyrosine kinases, along with sustained production of ac-
tivating ligands, such as mutated K-RAS in lung and colon cancer,
and B-RAF in melanoma [35]. Additionally, oxidative stress in-
duced by exogenous hydrogen peroxide can trigger ligand-in-
dependent EGFR activation either through phosphorylation of re-
ceptor tyrosine kinase or oxidative inactivation of phosphatases
[36,37]. Unlike ERK½, JNK normally acts as tumor suppressor that
triggers apoptosis in response to various stresses. Therefore, JNK
suppression in cancer cells could sustain their survival due to
enhanced resistance to apoptotic signals [38].
The tumor suppressor p38 MAPK also opposes growth signals
transduced by ERK½, and is required for cancer cells dormancy.
Down-regulation of p38 MAPK in various types of cancer promotes
survival of tumor cells [39].
Intracellular oxidative stress regulates JNK and p38 activity [40]
through the redox-sensitive complex ASK-1-thioredoxin. ASK-1 is
a member of the MAPKKK superfamily that is maintained inactive
by its binding to reduced thioredoxin in non-stressed cells. If
thioredoxin gets oxidized, it disassociates from ASK-1, leading to
activation of JNK and p38 through oligomerization of ASK-1 [41].
MAPKs integrate multiple signals and direct them via tran-
scription factors towards the nucleus for mounting clear-cut cel-
lular responses in cancer, such as resistance to oxidative stress,
proliferation, metastasis or apoptosis. The interaction speciﬁcity
within the MAPK pathway and the interactions of selectively ac-
tivated MAPK members with transcription factors is guided by
scaffolding proteins as crosstalk integrators [42].
3.2. FOXO transcription factors
Downstream of MAPK signaling pathways, important decision
regarding the cell fate is taken at the level of the forkhead box O
(FOXO) family of transcription factors (FOXO1, FOXO3, FOXO4 and
FOXO6). The ROS-sensitive FOXOs maintain cellular homeostasis
and coordinate cell responses for counteracting environmental
aggressions (growth factor deprivation, metabolic and oxidative
stress), hence acting as tumor suppressors that control the cell
cycle [43,44]. FOXOs also confer resistance to moderate oxidative
stress through transcription of antioxidant genes, such as those
encoding for superoxide dismutase, catalase and peroxyredoxins
[43]. In case of aggressive oxidative stress, FOXOs promote apop-
tosis by inducing the expression of pro-apoptotic factors (FAS li-
gand, Bim, bNIP3 and Bcl-XL) [45].
In normal cells, antagonistic mechanisms regulate FOXOs ac-
tivity, depending on the context: (1) insulin and growth factors
signaling through the PI3K/Akt pathway inhibits FOXO transcrip-
tional activity by phosphorylation and subsequent cytoplasmic
retention of FOXOs through increased binding to their 14–3–3
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response to an intense oxidative burst augments its transcriptional
activity and tumor suppressor function [47]. Concurrently, JNK
inhibits insulin signaling, hence overruling FOXO inhibition by
growth factors [43]; (3) down-regulation of FOXO by poly-
ubiquitylation in the cytoplasm favors its proteosomal degradation
[48].
The PI3K/Akt signaling pathway is critically involved in reg-
ulating cell proliferation and survival, glucose metabolism, gen-
ome stability, and neo-vascularization [49]. It is over-expressed or
highly activated in many types of tumors, and most of components
are involved in tumorigenesis, either as oncoproteins or tumor
suppressors [50]. Over-expression or constitutive activation of the
PI3K/Akt pathway in tumor cells leads to the inhibition of FOXO
tumor suppressors by phosphorylation and cytoplasmic seques-
tration [46]. Meanwhile, FOXO acetylation shifts FOXO-mediated
gene expression from an apoptotic to a pro-survival pattern [51].
3.3. The Keap1-Nrf2 system
The Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor
E2-related factor 2 (Nrf2) system is critically involved in cell de-
fense against various endogenous and exogenous stresses [52].
Keap1 and to a lesser extent Nrf2 are redox sensors, and the
transcription factor Nrf2 transactivates genes that encode anti-
oxidant enzymes. Nrf2 is retained in the cytoplasm through in-
teraction with Keap1, which controls proteosomal degradation of
ubiquitylated Nrf2 in a redox-dependent manner. Oxidative stress
causes disulﬁde bond formation between Cys273 and Cys288 in
Keap1, leading to Nrf2 release and its nuclear translocation for
transcriptional activity. Additionally, multiple external stimuliFig. 1. Critical turning points of signinduce the activation of MAPK and PI3K, which in turn phos-
phorylate Nrf2 at Ser40 to dissociate from Keap1 [53].
In cancer cells, Keap1 mutations or epigenetic modiﬁcations in
its promoter region lead to Keap1 inactivation or reduced ex-
pression, hence up-regulating Nrf2 activity and consequent
transactivation of antioxidant genes [54]. Therefore, cancer cells
get shielded against oxidative stress and gain a survival advantage.
Alternatively, Nrf2 repression by oncogene-induced activation of
the Ras/Raf/ERK pathway may be an adaptive response for certain
incipient cancers to acquire a pro-oxidant state that favors cell
survival and tumor growth [55]. Accordingly, activation of Nrf2
may be a valuable preventive strategy to avoid tumorigenesis in
patients with cancer risk Fig. 1.4. Inﬂammation in the tumor niche
4.1. Communication in the tumor niche
Tumor progression is underlined not only by epi- or genetic
changes and distorted signal transduction, but also by an active
crosstalk of cancer cells with the surrounding stroma [56]. Fibro-
blasts, immune, endothelial and mesenchymal cells, all immersed
in an oriented cellular matrix, build the tumor niche and its par-
ticular oxidative, acidic, inﬂammatory and hypoxic milieu that
drives tumors towards a more aggressive phenotype [57].
Autocrine and paracrine communication in the tumor niche is
mediated by “soluble” factors, adhesion molecules and gap junc-
tion channels. Additionally, exosomes of endolysosomal origin and
plasma membrane-derived microvesicles carry a load of bioactive
molecules that faithfully reﬂect the physiological state of the cellsaling pathways in cancer cells.
Fig. 2. Inside the tumor niche – cellular communication in stressful conditions.
Fig. 3. Players of the oxidative DNA damage response (DDR).
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make enclosed molecules to be more stable than the corre-
sponding soluble forms, hence accurately delivering messages
over a long distance [58]. Extracellular vesicles released by most
malignant and normal cells, possibly due to tumor-speciﬁc hy-
poxia [59] and acidosis [60], have been recently demonstrated to
spread within the tumor niche pathologic signals (oncogenes and
other pro-tumorigenic factors) [61,62]. These inter-cellular signa-
losomes trigger secretion of tumor-promoting growth factors, cy-
tokines, and angiopoietic factors by stromal and immune cells,
hence sustaining angiogenesis, local inﬂammation and metastasis
[63]. Moreover, exosomes released by cells exposed to oxidative
stress have the ability to induce stress tolerance in neighboring
cells through mRNA shuttle [64], thus favoring their oncogenic
transformation Fig. 2.
4.2. Tumor-associated inﬂammation
Tumor-associated inﬂammation is mediated by cytokines,
chemokines, growth factors and ROS released by almost all cells in
the tumor niche [65,66]. Inﬂammation can drive tumor progres-
sion by increasing mutation rates and by enhancing the survival of
mutated cells [67] (Fig. 3). The tumor-associated inﬂammation
resembles to a defective wound healing process, associating long-
lasting and self-sustained inﬂammation with excessive tissue re-
modeling and loss of tissue architecture.
Stressed and/or damaged cells within the tumor niche release
“danger” signals (DAMPs, danger-associated molecular patterns),
which elicit an inﬂammatory response in neighboring cells (the
danger theory) [68]. DAMPs are nuclear and cytosolic proteins
(HMGB1, shock proteins, the S100 family of calcium-binding pro-
teins, histones, IL-1), nucleotides and their metabolites (uric acid),
along with extracellular molecules (hyaluronan, heparin sulfate)
[69].
Mitochondria have recently emerged as key source of DAMPs
[70] which signals to neighboring cells the local oxidative injury.
Some DAMPs, like the nuclear and cytosolic HMGB1, are sensors ofthe intracellular oxidative status, being released or exposed fol-
lowing oxidation of critical cysteine residues [71]. The release of
HMGB1 from the nucleus leaves DNA unprotected against oxida-
tive stress and fosters genomic instability in the tumor niche [72].
Extracellular HMGB1 interacts with speciﬁc receptors on neigh-
boring cells (the receptor for advanced glycation end products,
toll-like receptors etc. [73]), and triggers angiogenesis and acti-
vation of endothelial cells, recruitment of immune cells, and an
overall inﬂammatory response to environmental stress or damage.
Both sided signaling mediated by DAMPs is tightly regulated by
the spatial and temporal distribution of ROS [74]. While in-
tracellular DAMPs are activated by oxidative stress, their pro-
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tracellular oxidative milieu [75].
The inﬂammatory environment in tumors is partly sustained by
tumor-resident macrophages, along with newly recruited mono-
cytes and neutrophils [76]. Leukocytes recruitment mediated by
chemotactic factors released by cancer and stromal cells is de-
pendent on the local vasculature network which exhibits an acti-
vated phenotype [77]. Cancer cells rely on this exogenous con-
tribution for survival, development and spreading. Due to their
high plasticity, cancer cells may even trans-differentiate into tu-
mor endothelial cells to sustain vasculo- and lymph-angiogenesis
[78]. Neutrophils and macrophages contribute to the enhanced
oxidative status in the tumor niche by producing considerable
amounts of ROS through the activation of NOX2 in response to
danger, damage or inﬂammatory stimuli [76].
Tumor-associated macrophages are a major source of pro-in-
ﬂammatory cytokines and chemokines, like TNFα, IL-1, IL-6 and IL-
8. The pleiotropic cytokine TNFα plays crucial roles in tumor de-
velopment and progression by stimulating the growth, prolifera-
tion, invasion and metastasis of cancer cells [79–81]. TNFα also
induces ROS production via NFκB activation by increasing the
transcription of various members of the NOX family. In turn, ROS
stimulate or inhibit multiple upstream and downstream compo-
nents of the NFκB pathway, depending on the cell type and the
context [82].
DAMPs and inﬂammatory cytokines trigger the activation of
inﬂammasomes in myeloid and epithelial cells (e.g. NLRP3 and
NLRC4 inﬂammasomes, respectively), resulting in production of
the pro-inﬂammatory cytokines IL-1β and IL-18that are critically
involved in various types of cancers [83]. In late stages of tumor
progression, inﬂammasomes may be constitutively activated [84].
Schematically, inﬂammasome activation is initiated by NFκB-
mediated transcription of pro-IL-1β and pro-IL-18 in response to
toll like receptors signaling, continued by activation of the cysteine
protease caspase-1 [85]. Most of NLRP3 inﬂammasome activators
induce ROS generation, partly through mitochondrial damage [86].
In turn, mitochondrial superoxide anion may prime the NLRP3
inﬂammasome by de-ubiquitination [87]. The antioxidant system
is turned on in response to the oxidative challenge, but can in-
directly sustain inﬂammation, as thioredoxin-interacting protein
binds to and activates the NLRP3 inﬂammasome after dissociating
from thioredoxin [88].
We emphasize herein the paradigm shift occurring in the last
decade, stating that ROS and cytokine production is not exclusively
conﬁned to phagocytes and immune cells, respectively. For ex-
ample, stromal carcinoma-associated ﬁbroblasts exhibit a parti-
cular inﬂammatory phenotype (myoﬁbroblastic) [89]. ROS pro-
duced by ﬁbroblasts carrying mitochondrial dysfunction, or hy-
poxia-related ROS production in mutated ﬁbroblasts can induce
their trans-differentiation into such myoﬁbroblasts [90]. Myoﬁ-
broblasts release multiple soluble factors, such as the chemokine
stromal-derived factor-1 that interacts with CXCR4 and promotes
tumor and stromal cell migration through matrix remodeling.
CXCR4 also triggers in cancer cells ROS production by NOX2 en-
zymes [91]. Moreover, ﬁbroblast-derived exosomes can sustain
cancer cell dynamics through Wnt signaling [92]. A vicious circle is
thus established, in which mutations in carcinoma cells drive al-
terations in the stroma that in turn facilitate carcinoma progres-
sion [93].
Cancer-associated inﬂammation has a particular proﬁle that
favors tumor growth, but inhibits the anti-tumor immune re-
sponse. For example, myeloid-derived suppressor cells are en-
riched in melanoma lesions and lymphatic organs during tumor
progression and inhibit tumor-reactive T cells [94]. Despite their
inﬂammatory phenotype, tumor-associated macrophages were
shown to induce immune suppression mediated by IL-10 and TGFβ[94]. Moreover, they contribute to the polarization of the local
immune response towards tolerogenic T regulatory cells (Treg)
[95]. Being more resistant to oxidative stress, immunosuppressive
Treg have a survival advantage over tumor-speciﬁc cytotoxic
TCD8þ lymphocytes in the oxidative environment of tumors [96].5. Using ROS for cancer therapy
ROS sustain tumorigenesis and cancer progression, but are also
efﬁcient therapeutic tools to ﬁght cancer. By increasing ROS levels
in the tumor niche the damaging face of ROS can be brought to the
forefront to overcome the growth-promoting action of metabolic
ROS in cancer cells.
5.1. Oxidative stress-based therapies in cancer
Several therapeutic strategies, such as radiotherapy and pho-
todynamic therapy, were speciﬁcally designed to increase ROS
levels in tumor cells to elicit their death through sudden and in-
tense oxidative stress. By generating a therapy-induced overload
of ROS in cancer cells the oxidative threshold separating survival
from death could be exceeded. Due to the high intrinsic oxidative
activity of cancer cells and their faulty programming, less addi-
tional ROS are required compared to normal cells for triggering
cell death. Levels of ROS that are cytotoxic for cancer cells induce
less drastic effects in normal cells, which have a lower oxidative
status and are endowed with efﬁcient tools to repair ROS-induced
injuries within certain limits. Nevertheless, precise targeting of
oxidative stress-based therapies to the diseased tissue is a priority,
aiming to protect normal tissues against deleterious action of
“therapeutic” ROS.
Tumor cells have different intrinsic susceptibilities to oxidative
stress. A major drawback of oxidative stress-based therapies relies
in the outstanding resistance of cancer stem cells (CSCs). These
cells have the ability to self-renew, to differentiate into multiple
lineages and to initiate tumors, hence being responsible for the
uncontrolled growth of tumors, maintenance of minimal residual
disease and tumor recurrence following therapy [97]. CSCs re-
sistance relies on enhanced repair mechanisms, up-regulated cell
cycle control, over-expression of antioxidant enzymes and efﬁca-
cious free radical scavenging [98]. Various molecular networks
regulate CSCs and their adaptive responses to hypoxia and oxi-
dative stress in the tumor niche. For example, the PI3K/PTEN/AKT/
mTOR pathway controls ROS levels in CSCs by regulating the nu-
clear localization of FOXO and the consequent over-expression of
antioxidant enzymes [99]. Additionally, constitutive activation of
Nrf2 in CSCs inhibits their differentiation by reinforcing anti-
oxidant shielding [100]. Therefore, Nrf2 inhibitors may sensitize
CSCs and cancer cells to the effects of oxidative stress-based
therapies by down-regulating their antioxidant response [101].
Delivery of Nrf2 inhibitors should be highly targeted towards the
tumor for avoiding down-regulation of the intrinsic antioxidant
system of normal cells.
Tumor heterogeneity derives also from the non-uniform spatial
distribution of microenvironmental stresses, such as hypoxia,
acidosis, oxidative stress and nutrient deprivation [102]. Since
oxidative stress-based therapies are particularly dependent on the
local supply of molecular oxygen, cancer cells placed in hypoxic
regions might not respond to such therapies. Accordingly, in vivo
imaging of the hypoxia map could guide the therapeutic strategy
for eradicating such “hidden” cells.
Radiotherapy is the prototype of oxidative stress-based therapy.
Ionizing radiation (IR), electromagnetic or particulate, can directly
disrupt atomic structures in cells, resulting in major chemical and
biological changes. At therapeutically relevant doses, direct
G. Manda et al. / Redox Biology 5 (2015) 347–357 353interaction of IR with nuclei is low and its indirect action through
water radiolysis prevails. As described by Azzam et al. (2012) [103],
IR energy deposition results in the generation of secondary elec-
trons and unstable species, which further produce radicals and
molecular products of radiolysis, distributed in a highly hetero-
geneous track structure (1012 s). Chemically reactive species
further diffuse and react with one another and with biologic
structures (106 s). In an aerobic cellular environment water
radiolysis generates superoxide anion, hydroxyl radical, hydrogen
peroxide, depending on the linear energy transfer (LET) of the ir-
radiating particles. For example, hydrogen peroxide prevails over
hydroxyl radical with increasing LET, while high LET particles
mainly produce superoxide anion. Although this spectrum of ROS
is similar to that produced by metabolic processes, biologically-
relevant differences are to be noticed, mainly because IR generates
almost instantaneously high concentrations of localized ROS that
lead to clustered lesions and extensive, irreparable oxidative
injury.
Photodynamic therapy (PDT) is another strategy to increase ROS
to cytotoxic levels within cancer cells [104,105]. Brieﬂy, cells are
loaded with a light-sensitive photosensitizer (PS), which is acti-
vated by irradiation with light of appropriate wavelength, and
generates a localized burst of singlet oxygen. Currently available
PSs preferentially accumulate into tumors. Their intake by normal
tissues cannot be completely avoided and therefore PSs are de-
signed to have low dark toxicity. Targeting of PDT towards the
tumor and sparing of normal tissue is achieved by precise light
irradiation of the diseased tissue using ﬂexible ﬁber-optic devices.
The use of 600–800 nm light is recommended for PS activation
due to the low tissue-damaging action of red to far red light.
The intracellular localization of PS dictates the distribution of
the deleterious light-elicited oxidative stress mediated by singlet
oxygen. Available PSs localize mostly in lipid membranes, lyso-
somes, mitochondria and/or endoplasmic reticulum [104]. Unlike
IR, PDT does not target the nucleus and this may represent a
therapeutic advantage by avoiding the spreading of genomic in-
stability. The short lifetime of singlet oxygen limits its diffusion to
only 10–55 nm [106], hence deciding on the action ﬁeld of PDT.
For improving PDT efﬁcacy, huge efforts are now focused on
real-time monitoring of PDT-associated photoreaction for adjust-
ing the irradiation parameters during the therapeutic procedure.
For singlet oxygen dosimetry one may take advantage of the
ﬂuorescent light emitted by the excited PS [107] or of the singlet
oxygen phosphorescence at 1270 nm [108].
5.2. Types of cell death induced by oxidative stress-based therapies
Excessive oxidative stress can induce directly irreparable cel-
lular lesions, or may commute the signaling machinery from pro-
survival to death signals delivery. The lethal action of oxidative
stress-based therapies in the tumor niche is dependent on the
quality of the elicited oxidative burst (intensity and intracellular
localization), target cell susceptibility to oxidative stress (genetic
background, oxidative status, repair mechanisms), and the global
microenvironment response to the oxidative challenge. A non-
physiologically intense and sudden sparkle of intracellular ROS
generated by IR generally leads to clustered DNA double strand
breaks which fail to be repaired or are misrepaired, either because
cells are not prepared to face such an aggression, or their enzy-
matic repair mechanisms are defective. We highlight several
cancer-speciﬁc mutations and polymorphic variants of cancer
susceptibility genes associated with genomic instability, which
support cancer progression, and underlie cellular responses to
anti-cancer therapies: (a) ataxia telangiectasia mutated (ATM)
which is central to cell cycle checkpoint responses initiated by
DNA double-strand breaks by phosphorylating oncogenes like p53and Chk2 [109]; (b) the Mre11/Rad50/Nbs1 complex which re-
cruits ATM to DNA double strand breaks and mediates non-
homologous recombination repair, predominantly during the G1/
early S phase [110], (c) the breast cancer predisposition genes
BRCA1/2 which are phosphorylated by Chk2 and mediate homo-
logous recombination in the S phase [111]. IR-induced DNA da-
mage triggers mitotic cell death after several cell cycles, and such
cancer cells can progress either to apoptosis or necrosis depending
on the context [112]. Cancer cells exhibiting deﬁcient apoptotic
response may become senescent [113], exit from the cell cycle, but
persist in the tumor and release pro-inﬂammatory cytokines and
growth factors. Part of the senescent cells may recover and even
acquire a more aggressive malignant phenotype, along with in-
creased resistance to therapy due to genetic instability [114]. Ad-
ditionally, the crosstalk between senescence and autophagy in
cancer cells may contribute to tumor dormancy [115].
Oxidative stress-based therapies may induce apoptosis in-
directly in response to oxidative and metabolic stresses. This death
mechanism is mostly conﬁned to “normal” cells in the tumor
niche, as a common stress response mediated by the activation of
JNK and p38 MAPK [116]. JNK1 triggers apoptosis in response to
stress, but induces also compensatory proliferation of the neigh-
boring non-apoptotic cells [117]. Unlike normal cells, cancer cells
are endowed with anti-apoptotic mechanisms that reinforce their
survival in noxious conditions. The synergy between growth-in-
ducing oncogenes, like c-Myc, and over-expression of the cell
death inhibitor Bcl-2, along with mutation-induced functional loss
of the tumor suppressor p53, all can block the apoptotic machin-
ery in cancer cells, hence supporting malignancy and resistance to
therapy [118]. Agents that inhibit apoptosis might be useful in
conjunction with oxidative stress-based therapies for reducing
dose-limiting side-effects due to apoptosis of normal cells [116].
5.3. Distant effects of oxidative stress-based therapies
The outcome of oxidative stress-based therapies depends not
only on the death of directly irradiated cells, but also on the pat-
tern of delayed effects in the neighboring area (bystander effects).
Non-irradiated cells in the close vicinity of oxidative stress-da-
maged cells are induced to exhibit a similar phenotype char-
acterized by DNA strand breaks, point mutations, gene deletions
and micronucleation, along with increased levels of ROS and in-
ﬂammatory reactions [119]. Such delayed cellular changes are
transmitted to progenitors for several cellular doublings [120].
Accordingly, therapy-damaged cancer cells may trigger the
death of neighboring non-irradiated cell, hence enlarging the
therapeutic action area of targeted oxidative stress-based therapy
(biologic penumbra). This contributes to tumor eradication more
than expected from the initial therapy ﬁeld. Unfortunately, the
bystander effect may also injure neighboring normal tissue, hence
increasing therapy side effects. Alternatively, signals delivered by
oxidative stress-injured cells may induce adaptive responses in
neighboring cells by up-regulation of repair mechanisms, such as
those mediated by p53 [121]. Therefore, the bystander effect can
limit in certain cases tumor cells response to current and future
therapies, and may also support the development of secondary
cancers.
The transfer of information between cells is achieved by gap
junctions, soluble factors and exosomes in the tumor niche, as
mentioned in the section “Inﬂammation in the tumor niche”. Ir-
radiated cancer cells carrying profound DNA damage and meta-
bolic alteration are signaling to neighboring cells the oxidative
damage by releasing ROS, oxidized extracellular DNA, danger sig-
nals (HMGB1) and a plethora of pro-inﬂammatory cytokines
(TNFα, IL-1β, IL-6, IL-8, IL-33, TGFβ1) [122]. The exact mechanism
underlining the bystander effect is still not known. It is improbable
Fig. 4. Distant effects of ROS-based therapies – propagation of signals delivered by oxidative stress-injured cells.
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heterogeneous tumor niche. One could consider that distinct cell
types may not use the same panel of molecules for inter-cellular
communication. Moreover, soluble factors released by injured
cancer cells have a short-ranged action due to interaction with
speciﬁc receptors on neighboring cells, or attachment to cellular
matrix components. Thus, sequential and polarized inter-cellular
signaling, mediated by different cell-speciﬁc molecules and signal
transduction mechanisms, may hypothetically account for distant
effects of oxidative stress-based-therapies (Fig. 4).
In particular conditions, oxidative stress-based therapies can
trigger the immunogenic cell death of cancer cells: tumor antigens
are revealed and become accessible for uptake by dendritic cells,
which further elicit antigen-speciﬁc cytotoxic T cell responses and
production of tumor-speciﬁc antibodies [123]. The enhanced tu-
mor-speciﬁc immunity and blood cytokines underline the distant
effect of oxidative stress-based therapies (abscopal effect), through
which regression of distant metastatic cancer may occur [124].
Therefore, combinations of radiotherapy/chemotherapy and im-
munotherapy are currently under development in clinical settings.6. Future perspective
Tumor is a web of interconnected genomic and signal trans-
duction alterations in a stressful local environment. Using systems
biology for investigating the sophisticated network of events in
the tumor niche, along with a theory unifying common molecular
pathways underlying the pressure of various stresses, might be a
fruitful approach in the endeavor to understand cancer and to
design innovative therapeutic strategies to ﬁght against it. Taking
advantage of the new “omic” technologies for drawing meaningful
molecular maps of pathologic events, in-depth investigations are
under development for getting the “big picture” and for identify-
ing new therapeutic targets addressing the distorted redox bal-
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